Helen Heslop, MD
Baylor College of Medicine
17
16
6
N/A
0
16
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+18 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (17)
Showing 10 of 17 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Carlos Ramos, MD
The Methodist Hospital Research Institute
Shared therapeutic areas:
Worked with same sponsors:
Premal Lulla, MD
The Methodist Hospital Research Institute
Shared therapeutic areas:
Worked with same sponsors:
Carlos A Ramos, MD
The Methodist Hospital Research Institute
Shared therapeutic areas:
Worked with same sponsors:
Sairah Ahmed, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
LaQuisa Hill, MD
The Methodist Hospital Research Institute
Shared therapeutic areas:
Worked with same sponsors:
Cliona Rooney, PhD
Baylor College of Medicine
Shared therapeutic areas:
Worked with same sponsors:
Kurt Gunter, MD
Cell Medica
Shared therapeutic areas:
Worked with same sponsors:
Malcolm Brenner, MD
The Methodist Hospital Research Institute
Shared therapeutic areas:
Worked with same sponsors:
Sarah Whittle, MD
Baylor College of Medicine
Shared therapeutic areas:
Worked with same sponsors:
Ann Leen, PhD
Baylor College of Medicine
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (17)
Showing 17 of 17 trials
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
TAA-Specific CTLS for Solid Tumors (TACTASOM)
Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma
Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL
Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)
ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD)
All 17 trials loaded